Industry

Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1 CONTENT showed that Dysport® decreased incontinence episodes, detrusor pressure and increased bladder capacity versus placebo, and improved quality of life1 PARIS–(BUSINESS WIRE)–Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Human Growth Hormone Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The global market for Human Growth Hormone Drugs estimated at US$3.3 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2026, growing at a CAGR of 3.5% over the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmacy Repackaging Systems – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The global market for Pharmacy Repackaging Systems estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.2 Billion by 2027, growing at a CAGR of 7.5% over the analysis period … [Read more…]

SURESNES, France–(BUSINESS WIRE)–AlgoTx announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA), for the development of ATX01 in chemotherapy-induced neuropathic pain. “The FDA’s Fast Track designation of ATX01 reflects the critical unmet medical need of 60% of chemotherapy patients suffering from chemotherapy-induced neuropathic pain,” said Stéphane Thiroloix, … [Read more…]

Expansion of European business development team supports next phase of growth for Metrion’s ion channel drug discovery services CAMBRIDGE, England–(BUSINESS WIRE)–Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion … [Read more…]

In Long-Term Exploratory Analysis, TAK-003 Prevented 84% of Hospitalizations and 61% of Symptomatic Dengue Illness Overall, with No Identified Important Safety Risks Results Through 4.5 Years Conclude the Evaluation of the Primary Two-Dose Series of TAK-003 TAK-003 is Currently Undergoing Regulatory Review for Potential Licensure in Both the European Union and Select Dengue-Endemic Countries OSAKA, … [Read more…]

ALLENTOWN, Pa.–(BUSINESS WIRE)–Yourway, the only truly integrated premium courier and clinical packager in the clinical trials supply chain market, today announced construction of a new flagship European depot in Dublin, Ireland. The new GMP facility is being purpose-built to support Yourway’s clinical trials offering, including premium courier services, primary and secondary packaging, and temperature-controlled storage … [Read more…]

Results of PXL065 Phase 2 (DESTINY-1) trial in NASH expected in Q3 2022 LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that the U.S. Patent and Trademark Office (PTO) has … [Read more…]

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in-person of a member of Sensorion’s senior management in the Gene Therapy Development and Manufacturing conference … [Read more…]

BEIJING–(BUSINESS WIRE)–SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received the World Health Organization (WHO) prequalification for its Poliomyelitis Vaccine (Vero Cell, Inactivated Sabin strains) (“sIPV”) on June 2, 2022. The vaccine will be available for United Nations (UN) agencies to purchase … [Read more…]